Companies: 10,795·Total market cap: $144.5T
Aptose Biosciences Inc.

Aptose Biosciences Inc.

APTONASDAQHealthcare
$1.71
+$1.71(+100.00%)
Market Cap$4364655
P/E Ratio
52W High$43.191
52W Low$1.1

Aptose Biosciences Inc. (APTO) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

apto · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Aptose Biosciences Inc. (APTO) measures how much investors pay for each dollar of the company's trailing earnings. APTO's current PE ratio of 0.79x is calculated by dividing its stock price of $1.71 by its TTM earnings per share of $2.17. −98.7% discount vs 5Y avg 62.2x

0.79x
P/E Ratio (TTM)98.7%

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2026 est. EPS $-5.65
Based on 1 analyst
EPS (TTM)
$2.17
TTM · diluted EPS
PEG Ratio
-0.01
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aptose Biosciences Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2007 – 2025 · Annual
PE Ratio (TTM)
5Y Avg 62.2x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Aptose Biosciences Inc.
Aptose Biosciences Inc.You
APTO
$4M0.79x$2.17
Affimed N.V.
Affimed N.V.
AFMD
$3MN/A-$7.09
Aravive, Inc.
Aravive, Inc.
ARAV
$3MN/A-$2.22
Atreca, Inc.
Atreca, Inc.
BCEL
$4MN/A-$2.52
Gamida Cell Ltd.
Gamida Cell Ltd.
GMDA
$4MN/A-$0.42
Gritstone bio, Inc.
Gritstone bio, Inc.
GRTS
$4MN/A-$1.20
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
IDRA
$0MN/A-$7.17

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 20 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$0.00
2024-12-31
FY2024
$-5.73
2023-12-31
FY2023
$-7.58
2022-12-31
FY2022
$-6.80
2021-12-31
FY2021
$-11.01
2020-12-31
FY2020
$-9.30
2019-12-31
FY2019
$-7.86
2018-12-31
FY2018
$-12.97
2017-12-31
FY2017
$-7.84
2016-12-31
FY2016
$-16.31

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Aptose Biosciences Inc. (APTO) measures how much investors pay for each dollar of the company's trailing earnings. APTO's current PE ratio of 0.79x is calculated by dividing its stock price of $1.71 by its TTM earnings per share of $2.17.

PE Ratio = Stock Price ÷ EPS (TTM)
= $1.71 ÷ $2.17 = 0.79x
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

APTO pe ratio · 6 questions

APTO's current PE ratio is 0.79x as of 2026-06-09, based on a stock price of $1.71 and TTM EPS of $2.17. Data sourced from Financial Modeling Prep via APTO's SEC 10-K and 10-Q filings.

APTO PE ratioWhat is APTO PE ratioCurrent PE ratio of APTOAPTO PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aptose Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09